Retension Pharmaceuticals, Inc. (RTSN) vs VAXART, INC. (VXRT)

Retension Pharmaceuticals, Inc. RTSN 10.58 −8.79%
VAXART, INC. VXRT 0.37 −7.50%

Retension Pharmaceuticals, Inc. and VAXART, INC. are both Biotechnology companies. Retension Pharmaceuticals, Inc. and VAXART, INC. are of similar size ($96.6M and $92.4M).

Metric	RTSN	VXRT	Biotechnology median
P/E	—	2.85	10.26
P/S	—	0.50	9.18
P/B	—	1.36	2.05
Price to free cash flow	—	2.81	24.81
EV/EBITDA	—	0.56	0.65
EV/Sales	—	0.14	8.98
Earnings yield	—	35.14%	(34.89%)
Free cash flow yield	—	35.55%	(24.52%)

Metric	RTSN	VXRT	Biotechnology median
Gross margin	—	100.00%	65.16%
Operating margin	—	16.63%	0.00%
Net margin	—	16.02%	0.00%
Free cash flow margin	—	17.64%	0.00%
Return on equity	—	62.42%	(50.12%)
Return on assets	—	16.26%	(45.60%)
Return on invested capital	—	2,542.26%	0.00%

Metric	RTSN	VXRT	Biotechnology median
Revenue growth (TTM)	—	22.31%	6.26%
EPS growth (last fiscal year)	—	121.21%	29.88%
Revenue growth, 5-year CAGR	—	125.76%	9.75%
Net income growth, 5-year CAGR	—	0.00%	0.00%

Metric	RTSN	VXRT	Biotechnology median
Debt to equity	—	0.00	0.00
Current ratio	—	1.71	4.89
Net debt to EBITDA	—	(2.42)	1.01

Metric	RTSN	VXRT	Biotechnology median
Dividend yield	—	—	0.41%
Payout ratio	—	—	—

Metric	RTSN	VXRT	Biotechnology median
Market cap	96.61m	92.41m	172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack